TADALAFIL VERSUS SILDENAFIL CITRATO NEL TRATTAMENTO DELLA DISFUNZIONE ERETTILE (DE): LA PREFERENZA DEI PAZIENTI ITALIANI E LE MOTIVAZIONI DELLA LORO SCELTA
Articolo
Data di Pubblicazione:
2008
Citazione:
TADALAFIL VERSUS SILDENAFIL CITRATO NEL TRATTAMENTO DELLA DISFUNZIONE ERETTILE (DE): LA PREFERENZA DEI PAZIENTI ITALIANI E LE MOTIVAZIONI DELLA LORO SCELTA / F., Fusco; A., Lembo; Ludovico, G. M.; PIROZZI FARINA, Furio Francesco; F. M., Motta; E., Spera; A., Casarico; R., Sicuteri; A., Rossi; V., Mirone. - In: UROLOGIA. - ISSN 0391-5603. - 75:(2008), pp. 24-31.
Abstract:
ABSTRACT: This is an open, multicentre, randomized, crossover study having the aim to evaluate
the preference for sildenafil citrate or tadalafil in a population of Italian patients affected
by ED, and to compare the efficacy and safety of these two drugs.
MATERIAL AND METHODS. From October 2003 to November 2004, thirteen Italian centers enrolled
ED patients (age >18) being in steady and naïve relation to ED treatment, both through
PDE5 inhibitors and any other treatment option. These patients were randomized to sildenafil
or tadalafil for 12 weeks, after which they were switched to the alternative treatment
for a further 12 weeks. The preference was evaluated through the Treatment Preference
Question (TPQ): “During this clinical trial you have taken tadalafil and sildenafil for the treatment
of erectile dysfunction. Which medication do you prefer to take for the next 8 weeks
of treatment?”. Moreover, patients were asked to express their preference as “strong” or
“moderate” and to answer some questions to clarify the reasons behind their preference.
SEP and IIEF-EF questionnaires were used for a comparison of efficacy.
RESULTS. 167 patients were enrolled, 144 of whom completed both treatment periods.
On being asked the TPQ, 75% of patients (n=108) decided to continue treatment with tadalafil,
in particular because it made it possible to have an erection many hours after taking the medication
(first or second preference reason for 64.8% of patients), while 25% (n=36) preferred
sildenafil (p=0.001). Both drugs improved the IIEF-EF and SEP scores compared to baseline,
with a slightly but significantly greater improvement with tadalafil for both parameters.
CONCLUSIONS. Tadalafil and sildenafil are both effective and well tolerated. Most of the patients
prefer tadalafil thanks to the possibility of having sexual intercourse many hours after
taking the medication. (Urologia 2008; 75: 24-31)
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
F., Fusco; A., Lembo; Ludovico, G. M.; PIROZZI FARINA, Furio Francesco; F. M., Motta; E., Spera; A., Casarico; R., Sicuteri; A., Rossi; V., Mirone
Link alla scheda completa:
Pubblicato in: